Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
0(0%)
Results Posted
75%(12 trials)

Phase Distribution

Ph phase_2
1
6%
Ph phase_1
2
13%
Ph phase_3
10
63%

Phase Distribution

2

Early Stage

1

Mid Stage

10

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
2(15.4%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
10(76.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(16)

Detailed Status

Completed16

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (15.4%)
Phase 21 (7.7%)
Phase 310 (76.9%)

Trials by Status

completed16100%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT01554618Phase 3

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Completed
NCT01144338Phase 3

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Completed
NCT02917057

Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

Completed
NCT02987348

Clinical Outcomes of Exenatide Versus Basal Insulin

Completed
NCT02974244

Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

Completed
NCT00894322Phase 1

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

Completed
NCT01104701Phase 2

A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

Completed
NCT00641056Phase 3

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

Completed
NCT00935532Phase 3

Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Completed
NCT00676338Phase 3

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Completed
NCT01029886Phase 3

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Completed
NCT00917267Phase 3

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

Completed
NCT01003184Phase 3

Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

Completed
NCT00877890Phase 3

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Completed
NCT00637273Phase 3

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

Completed
NCT00612794Phase 1

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16